γ secretase - apex @ ウィキ

γ-secretase
Semagacestat (LY450139) was a candidate drug for a causal therapy against Alzheimer's disease. It was originally developed by Eli Lilly and Élan, and clinical trials were conducted by Eli Lilly. Phase III trials included over 3000 patients,but in August 2010, a disappointing interim analysis, in which semagacestat performed less well than the placebo, led to investigators being instructed to tell subjects to stop taking the drug.

Mutations Tied to Alzheimer's and Rare Skin Disease

indomethacin

cancer treatment with gama-secretase inhibitors

皮膚とγセクレターゼ
http://blogs.yahoo.co.jp/tensugiy/20069404.html

http://www.sciencemag.org/cgi/content/abstract/science.1196284
γ-Secretase Gene Mutations in Familial Acne Inversa

http://www.cell.com/developmental-cell/abstract/S1534-5807%2804%2900339-9
γ-Secretase Functions through Notch Signaling to Maintain Skin Appendages but Is Not Required for Their Patterning or Initial Morphogenesis

http://ameblo.jp/kunotakayoshi/entry-10637190952.html
http://web.f.u-tokyo.ac.jp/~neuropsc/newpaper.html
http://www.sigma-aldrich.co.jp/up_catalog/SAJ1352.pdf

Gamma-secretase gene mutations link acne inversa

chronic pyoderma Gamma secretase